Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695513 | 0.93 | KDR (0.53) | MAPTFGFR2LMNAENPP3MEN1 | |
| SCHEMBL2207029 | 0.86 | FGFR2 (0.72) | MAPTFGFR2LMNARIPK2EGFR | |
| SCHEMBL2209936 | 0.82 | EGFR (0.61) | MAPTFGFR2LMNARIPK2EGFR | |
| SCHEMBL15664448 | 0.80 | FGFR2 (0.63) | MAPTFGFR2LMNARIPK2EGFR | |
| SCHEMBL2207343 | 0.80 | FGFR2 (0.63) | FGFR2RIPK2EGFREPHB2KDR | |
| SCHEMBL2208900 | 0.80 | FGFR2 (0.63) | MAPTFGFR2LMNAENPP3MEN1 | |
| SCHEMBL14047121 | 0.79 | FGFR2 (0.62) | MAPTFGFR2LMNAENPP3MEN1 | |
| SCHEMBL2210388 | 0.79 | FGFR2 (0.63) | MAPTFGFR2KDRTP53 | |
| SCHEMBL2211767 | 0.78 | FGFR2 (0.58) | MAPTFGFR2LMNAEGFRCA9 | |
| SCHEMBL3021512 | 0.78 | MAPT (0.81) | MAPTLMNACA9ENPP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | MAPT 1693/4885FGFR2 334/4885LMNA 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.